SSX1, Monoclonal Antibody

Monoclonal SSX1; Anti-SSX1; Synovial sarcoma X breakpoint 1; CT5.1; Cancer/testis antigen 5.1; SSRC; MGC150425; SSX1; SSX 1; SSX-1

For Research Use Only. Not for use in diagnostic procedures.

Monoclonal

IgG1

1D10

Mouse

SSX1 antibody was purified by affinity chromatography.

Supplied in PBS buffer, pH 7.3, containing 1% BSA, 50% glycerol and 0.02% sodium azide.

500 ug-1 mg/ml (lot specific)

Store at 4 degree C for short term storage. Aliquot and store at -20 degree C for long term storage. Avoid repeated freeze/thaw cycles.

Small volumes of anti-SSX1 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Mouse monoclonal SSX1 antibody

Cancer

Flow Cytometry (FC/FACS), Immunofluorescence (IF), Western Blot (WB)

FC: 1:100
IF: 1:100
WB: 1:2000

Flow Cytometric analysis of HEK293T cells transfected with either recombinant SSX1 protein (red) or empty vector (blue) stained using SSX1 antibody

Western Blot analysis of HEK293T cell lysates (5 ug) transfected with either recombinant SSX1 protein (Right) or empty vector (Left) detected with SSX1 antibody

Immunofluorescent staining of COS7 cells transiently transfected with recombinant SSX1 protein using SSX1 antibody

21,931 Da

synovial sarcoma, X breakpoint 1

protein SSX1

Protein SSX1

CT5.1  [Similar Products]

SSX1_HUMAN

The product of this gene belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneous humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. This gene, and also the SSX2 and SSX4 family members, have been involved in t(X;18)(p11.2;q11.2) translocations that are characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are likely responsible for transforming activity. Alternative splicing of this gene results in multiple transcript variants. A related pseudogene has been identified on chromosome X. [provided by RefSeq, Jul 2013]

SSX1: Could act as a modulator of transcription. A chromosomal aberration involving SSX1 may be a cause of synovial sarcoma. Translocation t(X;18)(p11.2;q11.2). The translocation is specifically found in more than 80% of synovial sarcoma. The fusion products SSXT-SSX1 or SSXT-SSX2 are probably responsible for transforming activity. Heterogeneity in the position of the breakpoint can occur (low frequency). Belongs to the SSX family.

Protein type: Oncoprotein; Cancer Testis Antigen (CTA)

Chromosomal Location of Human Ortholog: Xp11.23

Cellular Component: nucleus

Molecular Function: nucleic acid binding; transcription corepressor activity

Biological Process: transcription, DNA-dependent; regulation of transcription, DNA-dependent

Disease: Sarcoma, Synovial

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.